A F Chan1, J F Mortola, S H Wood, S S Yen. 1. Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla.
Abstract
OBJECTIVE: To test whether progesterone or progesterone receptors are important mediators of premenstrual syndrome (PMS) and whether progesterone antagonist RU 486 would alleviate symptoms. METHODS: Following extensive screening including physical and psychological assessment, seven women with severe PMS participated in a 6-month, randomized, double-blind, placebo-controlled, crossover study. The treatment included 3 months of low-dose RU 486 (5 mg alternate days for four doses, beginning 3 days after the urinary LH surge) or placebo, administered in a similar fashion. Symptoms were evaluated using the Calendar of Premenstrual Experiences, Beck Depression Inventory, State-Trait Anxiety Inventory, and the Profile of Mood States. RESULTS:Symptoms of PMS were similar during RU 486 and placebo treatments. CONCLUSION: Luteal-phase administration of low-dose RU 486 does not significantly reduce the physical or behavioral manifestations of PMS.
RCT Entities:
OBJECTIVE: To test whether progesterone or progesterone receptors are important mediators of premenstrual syndrome (PMS) and whether progesterone antagonist RU 486 would alleviate symptoms. METHODS: Following extensive screening including physical and psychological assessment, seven women with severe PMS participated in a 6-month, randomized, double-blind, placebo-controlled, crossover study. The treatment included 3 months of low-dose RU 486 (5 mg alternate days for four doses, beginning 3 days after the urinary LH surge) or placebo, administered in a similar fashion. Symptoms were evaluated using the Calendar of Premenstrual Experiences, Beck Depression Inventory, State-Trait Anxiety Inventory, and the Profile of Mood States. RESULTS: Symptoms of PMS were similar during RU 486 and placebo treatments. CONCLUSION: Luteal-phase administration of low-dose RU 486 does not significantly reduce the physical or behavioral manifestations of PMS.
Authors: Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers Journal: Arch Womens Ment Health Date: 2013-04-27 Impact factor: 3.633